Corey Williams

rss feed

Corey Williams's Latest Posts

EOT position update June 11, 2014

EOT position update June 11, 2014

| June 11, 2014

June 11, 2014 Market Snapshot If you were expecting a quiet summer for stocks… you’ve been disappointed by the market’s recent performance.  The ‘Sell in May and go away’ crowd is missing out on a whopper of a rally over the last month. Over the last month, the S&P 500 is up 4.3% and recently […]

Continue Reading

SET Portfolio Update June 2014

SET Portfolio Update June 2014

| June 3, 2014

June 10, 2014 So much for a quiet summer for stocks… The bulls have taken charge and the S&P 500 is surging to new all-time highs. As I pointed out last month, the ‘Sell in May and go away’ crowd was in danger of missing out on a big rally in stocks this summer.  And […]

Continue Reading

BST Position Update: June 3, 2014

BST Position Update: June 3, 2014

| June 3, 2014

June 3, 2014 . . . . Xencor (NASDAQ: XNCR) – Buy up to $9.40 XNCR is our latest addition to the portfolio.  This exciting clinical stage biotech is developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. We like Xencor for several reasons… Its proprietary drug development […]

Continue Reading

EOT trade alert May 30, 2014

EOT trade alert May 30, 2014

| May 30, 2014

May 30, 2014 Trade Alert: Buy GLOG August 2014 $25.00 Calls at $1.50 or better Company Background: GasLog (GLOG) owns and operates a fleet of liquefied natural gas (LNG) carriers. Short-Term Catalyst: GasLog is one of my favorite companies for several reasons. First off, they operate is an industry that’s undergoing a major transformation. Natural […]

Continue Reading

BST Trade Alert: May 29, 2014

BST Trade Alert: May 29, 2014

| May 29, 2014

May 29, 2014 Recommendation: Buy Xencor (NASDAQ: XNCR) up to $9.40 About the Company: Xencor is a clinical stage biotech developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer.  The company currently has six product candidates in clinical development internally and with large drug company partners. Each of these product […]

Continue Reading

EOT position update May 28, 2014

EOT position update May 28, 2014

| May 28, 2014

May 28, 2014 Market Snapshot I hope everyone enjoyed their Memorial Day holiday.  The unofficial start to summer has been accompanied by the typical slowdown on Wall Street. And the bears have been out in full force with their warnings for the demise of financial markets. The main thing they’ve been pointing to is the […]

Continue Reading

EOT position update May 21, 2014

EOT position update May 21, 2014

| May 21, 2014

May 21, 2014 Market Snapshot It’s been a quiet week on Wall Street with little in the way of economic news and quarterly earnings season winding down. The Q1 earnings season was a non-event.  Earnings for the companies in the S&P 500 are up around 1.3% and revenues are up around 0.9% over the last […]

Continue Reading

SET Monthly Issue May 2014

SET Monthly Issue May 2014

| May 20, 2014

May 2014 THE THEORY OF RELATIVE INTEREST RATES Former Chairman of the Federal Reserve, Ben Bernanke, has been making waves in the financial industry over the last few weeks. He’s been hosting private dinners with Wall Street elite.  It costs $250,000 to get a chair at one of these events.  So, I haven’t been myself.  […]

Continue Reading

EOT trade alert May 16, 2014

EOT trade alert May 16, 2014

| May 16, 2014

May 16, 2014 Trade Alert: Buy HIMX September 2014 $7.00 Calls at $1.10 or better Company Background: Himax Technologies (HIMX) is a fabless semiconductor maker in Taiwan.  They make semiconductors for flat panel displays like televisions, handheld devices, and liquid crystal on silicon micro-display. Short-Term Catalyst: HIMX’s stock price has been on a rollercoaster ride […]

Continue Reading

EOT position update May 14, 2014

EOT position update May 14, 2014

| May 14, 2014

May 14, 2014 Market Snapshot Large cap US stocks have regained some of their bullish momentum following the dramatic selloff in momentum growth stocks over the last few months. The S&P 500 hit a new all-time high of 1,902 yesterday.  It was the first time the index has crossed the 1.900 point threshold. Despite the […]

Continue Reading